AngioDynamics (NASDAQ:ANGO) Share Price Crosses Above 200 Day Moving Average – Should You Sell?

AngioDynamics, Inc. (NASDAQ:ANGO)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $11.95 and traded as high as $16.05. AngioDynamics shares last traded at $15.82, with a volume of 335,653 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ANGO. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research report on Friday, July 17th. Canaccord Genuity Group lifted their price target on shares of AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Finally, HC Wainwright increased their price target on AngioDynamics from $16.00 to $19.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $19.50.

AngioDynamics Stock Up 1.0%

The stock has a market capitalization of $653.84 million, a price-to-earnings ratio of -18.18 and a beta of 0.33. The business’s 50 day simple moving average is $13.73 and its 200-day simple moving average is $11.95.

AngioDynamics (NASDAQ:ANGO) last issued its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million during the quarter, compared to analysts’ expectations of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, analysts expect that AngioDynamics, Inc. will post -0.25 earnings per share for the current year.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction that occurred on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president directly owned 64,745 shares in the company, valued at $953,046.40. The trade was a 26.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AngioDynamics

Large investors have recently modified their holdings of the business. BlackRock Inc. bought a new position in shares of AngioDynamics in the 2nd quarter valued at $49,480,000. Millennium Management LLC lifted its position in shares of AngioDynamics by 28.1% during the 3rd quarter. Millennium Management LLC now owns 1,793,152 shares of the medical instruments supplier’s stock worth $20,030,000 after buying an additional 393,682 shares during the last quarter. Kotler Kevin acquired a new stake in AngioDynamics in the fourth quarter valued at about $21,997,000. Armistice Capital LLC boosted its stake in AngioDynamics by 3.9% in the fourth quarter. Armistice Capital LLC now owns 1,700,000 shares of the medical instruments supplier’s stock valued at $21,828,000 after buying an additional 64,000 shares in the last quarter. Finally, Weber Capital Management LLC ADV bought a new position in AngioDynamics in the fourth quarter valued at about $17,978,000. Institutional investors and hedge funds own 89.43% of the company’s stock.

About AngioDynamics

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.